Asthma Therapy in Pediatric Patients: A Systematic Review of Treatment With Montelukast Versus Inhaled Corticosteroids

2014 ◽  
Vol 28 (1) ◽  
pp. 51-62 ◽  
Author(s):  
Kristen Massingham ◽  
Shelley Fox ◽  
Arlene Smaldone
Keyword(s):  
Systematic Review ◽  
Pediatric Patients ◽  
Inhaled Corticosteroids ◽  
Asthma Therapy

Risk factors for the development of hypocalcemia in pediatric patients after total thyroidectomy – A systematic review

2021 ◽  
Vol 143 ◽  
pp. 110666
Author(s):  
Kung-Ting Kao ◽  
Elspeth C. Ferguson ◽  
Geoff Blair ◽  
Neil K. Chadha ◽  
Jean-Pierre Chanoine
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Total Thyroidectomy ◽  
Pediatric Patients

Hypoglycemia and Cortisol Deficiency Associated With Low-dose Corticosteroid Therapy for Asthma

PEDIATRICS ◽  
1996 ◽  
Vol 97 (6) ◽  
pp. 921-924
Author(s):  
Aaron L. Carrel ◽  
Stephanie Somers ◽  
Robert F. Lemanske ◽  
David B. Allen
Keyword(s):  
Adverse Effects ◽  
Low Dose ◽  
Inhaled Corticosteroids ◽  
Chronic Asthma ◽  
Asthma Therapy ◽  
Biochemical Alterations ◽  
Clinically Significant ◽  
Dose Corticosteroid ◽  
Oral Glucocorticoids ◽  
Cortisol Deficiency

Glucocorticoids are a cornerstone of the anti-inflammatory treatment of asthma. To minimize adverse effects of oral glucocorticoids (OGC), clinicians have used alternate-day oral or inhaled corticosteroids (IC), both generally considered safe for chronic asthma therapy in children. Although reversible growth suppression occasionally occurs, the general consensus is that, despite detectable biochemical alterations, these modes of therapy are not associated with clinically significant adrenal insufficiency.1 We report the occurrence of hypoglycemia due to cortisol deficiency during combination alternate-day oral and inhaled corticosteroids. CASE HISTORY A 3½-year-old boy with asthma was found one morning to be unarousable, limp, and blue around the lips.

Cognitive Deficits in Pediatric Craniopharyngioma: An Updated Review

2021 ◽  
Author(s):  
Abdulrahman Al-Mirza ◽  
Omar Al-Taei ◽  
Tariq Al-Saadi
Keyword(s):  
Systematic Review ◽  
Cognitive Impairment ◽  
Cognitive Deficits ◽  
Pediatric Patients ◽  
Memory Deficits ◽  
Neurological Deficits ◽  
Children And Adolescent ◽  
Visual Spatial ◽  
High Incidence ◽  
Standard Tests

AbstractCraniopharyngiomas (CP) are brain tumors that often occur in children and adolescent that results in many neurological and endocrinological disorders. The aim of this systematic review is to provide updated version of studies used to formalize standard tests used for cognitive impairment in pediatric patients with craniopharyngioma. A systematic review was conducted in PubMed, EBSCO, ProQuest, Science Direct, Wiley Online, and Springer to identify studies assessing cognitive impairment in pediatric patients with craniopharyngioma. Academic and learning dysfunctions were reported in seven studies among 41 of 178 patients (23%). Visual–spatial deficits were reported in six studies. Speech and verbal dysfunctions were reported in three studies. Memory deficits were reported in eight studies among 61 of 197 patients (31%). Motor dysfunctions were reported in five studies. Sleep related issues were reported in four studies among 33 of 70 patients (47.1%). Patients with treated pediatric CP demonstrate a high incidence of neurological deficits including cognitive dysfunctions. Academic and learning dysfunctions, visual–spatial deficits, speech and verbal dysfunctions, memory deficits, and sleep-related issues were the most commonly reported cognitive deficits in the present study.

scholarly journals Premedication with dexmedetomidine in pediatric patients: a systematic review and meta-analysis

Clinics ◽  
2014 ◽  
Vol 69 (11) ◽  
pp. 777-786 ◽  
Author(s):  
K Peng ◽  
SR Wu ◽  
FH Ji ◽  
J Li
Keyword(s):  
Systematic Review ◽  
Pediatric Patients ◽  
Meta Analysis

scholarly journals Impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review

BMJ Open ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. e037509
Author(s):  
Kimberley Sonnex ◽  
Hanna Alleemudder ◽  
Roger Knaggs
Keyword(s):  
Systematic Review ◽  
Chronic Obstructive Pulmonary Disease ◽  
Lung Function ◽  
Pulmonary Disease ◽  
Inhaled Corticosteroids ◽  
Smoking Status ◽  
Steroid Resistance ◽  
Cochrane Library ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

ObjectivesInhaled corticosteroids (ICS) reduce exacerbation rates and the decline in lung function in people with chronic obstructive pulmonary disease (COPD). There is evidence that smoking causes ‘steroid resistance’ and thus reduces the effect of ICS. This systematic review aimed to investigate the effect of smoking on efficacy of ICS in COPD in terms of lung function and exacerbation rates.DesignSystematic review.Data sourcesAn electronic database search of PubMed, Ovid MEDLINE, Ovid Embase and Cochrane Library (January 2000 to January 2020).Eligibility criteriaFully published randomised controlled trials (RCTs), in the English language, evaluating the use of ICS in COPD adults that stratified the participants by smoking status. Trials that included participants with asthma, lung cancer and pneumonia were excluded. The primary outcome measures were changes in lung function and yearly exacerbation rates.Data extraction and synthesisTwo independent reviewers extracted data and assessed risk of bias using the Cochrane Collaboration’s tool.ResultsSeven studies were identified. Four trials (17 892 participants) recorded change in forced expiratory volume in one second (FEV1) from baseline to up to 30 months after starting treatment. Heavier smokers (>36 pack years) using ICS had a greater decline in FEV1that ranged from −22 mL to −75 mL in comparison to lighter smokers. Smokers using ICS had mixed results in FEV1change: −8 mL to +77 mL in comparison to ex-smokers. Four trials (21 270 participants) recorded difference in COPD exacerbation rates at 52 weeks. The rate ratios favoured more exacerbations in ICS users who were current or heavier smokers than those who were ex-smokers or lighter smokers (0.81 to 0.99 vs 0.92 to 1.29).ConclusionsIn COPD, heavier or current smokers do not gain the same benefit from ICS use on lung function and exacerbation rates as lighter or ex-smokers do, however effects may not be clinically important.PROSPERO registration numberCRD42019121833

scholarly journals Clinical, radiological and laboratory characteristics of pediatric patients with COVID-19: Living systematic review

2021 ◽  
Author(s):  
Santiago Vasco-Morales ◽  
Cristhian Santiago Vasco-Toapanta ◽  
Paola Cristina Toapanta-Pinta
Keyword(s):  
Systematic Review ◽  
Pediatric Patients
Sign in / Sign up

Export Citation Format

Share Document